The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.
 
Sushma Jonna
No Relationships to Disclose
 
Ari M. Vanderwalde
Honoraria - AstraZeneca
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Genentech/Roche; Immunocore
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Polynoma (Inst); Replimune (Inst)
 
Jorge J. Nieva
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Western Oncolytics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Kelsey Anne Poorman
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Michelle Saul
No Relationships to Disclose
 
Xinyu von Buttlar
No Relationships to Disclose
 
John Y. Hu
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals